A striking question has been echoing through the halls of neuroscience conferences and medical research labs: why are women almost twice as likely as men to develop Alzheimer’s disease?

For years, the assumption lingered that the answer lay in women’s greater longevity. After all, age is the most significant risk factor for Alzheimer’s. Yet, as scientists have recently pointed out, this explanation falls short. The numbers simply do not add up. Women’s increased lifespan cannot alone account for such a profound disparity in disease rates.

The focus has now shifted to more intriguing possibilities—those rooted in biology rather than simple arithmetic. Experts are examining two major factors: chromosomes and menopause. These have become the centrepieces of a new wave of research, aiming to unravel the hidden mechanisms that may underpin this gender difference.

At the core of human genetics lies a fundamental distinction. Women possess two X chromosomes. Men have one X and one Y. The X chromosome is teeming with genes, far more so than its Y counterpart, which has been stripped of much genetic material over evolutionary time. This difference is not trivial. It could shape the very architecture of the brain and immune system, both crucial in Alzheimer’s development.

Interestingly, though one of the X chromosomes in women is largely silenced to prevent a double dose of proteins, this process is not perfect. Some genes on the silenced X remain active, leading to subtle differences in gene expression between women and men. These differences may play an unsuspected role in susceptibility to neurological diseases.

A recent review by Harvard published in Science Advances highlighted how genes on the X chromosome regulate not only the immune system but also critical aspects of brain function. The dosage of these genes varies between the sexes, potentially altering risk profiles for conditions like Alzheimer’s.

Chromosomes, however, are only part of the puzzle. Hormones form another vital piece. All humans produce oestrogen, progesterone, and testosterone, though in markedly different proportions. In women, oestrogen and progesterone dominate until menopause, typically occurring between the mid-40s and mid-50s. Menopause triggers a dramatic decline in these hormones.

Oestrogen is famous for its role in reproduction. Less well known is its impact on the brain. Research suggests it protects neurons and may influence how nerve cells communicate and clear toxic proteins. When oestrogen levels plummet during menopause, this protective effect may diminish, leaving the ageing female brain more vulnerable to Alzheimer’s pathology.

The study has explored this hormonal angle by examining hormone replacement therapy (HRT) in older women. Researchers found that women using HRT after age 70 showed significantly higher accumulations of tau protein in the brain—a hallmark of Alzheimer’s—alongside faster cognitive decline. Notably, these changes did not involve amyloid beta, another protein implicated in Alzheimer’s that currently serves as a primary drug target.

This finding supports what scientists term the “timing hypothesis.” Early studies suggested oestrogen could protect cognition if administered around the onset of menopause. However, larger trials like the Women’s Health Initiative upended expectations more than two decades ago by finding increased cognitive decline among women taking HRT later in life. Subsequent investigations clarified that younger women seemed to benefit from HRT, while older women faced increased risks.

Experts now advocate caution regarding HRT use in older age, emphasising that timing is everything. Short-term hormone therapy to manage menopausal symptoms appears safe if started early but should not be continued into old age due to potential adverse effects on the brain.

The complexity deepens when considering other neurological diseases. Multiple sclerosis and migraine are more common in women; Parkinson’s disease and certain brain tumours are more common in men. Even beyond Alzheimer’s, there appears to be an underlying biological pattern governing sex-based vulnerability. In some instances, such as migraine for women or Parkinson’s for men, those more commonly affected also tend to experience more severe symptoms.

What drives these disparities? Many point to differences at the genetic level—specifically those genes located on sex chromosomes—and how they interact with hormonal shifts across the lifespan. The immune system, regulated by several X-linked genes, also exhibits sex-specific properties that could affect neuro-degeneration.

Despite these clues, many unknowns remain. Data gaps persist—most notably about women’s reproductive histories and precise details of hormone therapy use—which limit researchers’ ability to draw definitive conclusions.

To address these limitations, scientists are now designing prospective studies that will map changes in blood biomarkers, brain imaging findings and cognitive performance across menopause and into later life. This approach could illuminate how changes at menopause set the stage for Alzheimer’s risk decades later.

As it stands, most large-scale research relies on secondary data—collections assembled for other purposes—which often lack crucial information such as when hormone therapy began or details about pregnancies and menstrual cycles. Experts stress that future studies must gather this missing data to untangle cause from correlation.

If successful, such research could pave the way for new forms of personalised medicine. Treatments tailored by biological sex or even individual hormonal history may one day offer better prevention or delay of Alzheimer’s onset.

Beyond immediate clinical implications, understanding these sex-related differences could shed light on why Alzheimer’s remains so enigmatic despite decades of research and billions spent on drug development. The hope is that by factoring in sex-specific biology—long neglected in clinical trials and basic research—scientists might unlock new therapeutic targets or preventive strategies.

Institutions such as Harvard Medical School and Massachusetts General Hospital are leading the charge in this renewed focus on sex differences in neurodegenerative disease. Their work underscores a broader shift in medicine towards greater nuance and individualisation.

The stakes could not be higher. Alzheimer’s disease remains incurable and devastating for millions worldwide. Its economic and emotional toll is immense. With populations ageing rapidly, especially in developed countries, there is urgent need for answers.

Efforts to understand why women are more susceptible to Alzheimer’s are part of a much larger movement to address gaps in knowledge about how sex shapes health and disease across the lifespan. For much of medical history, research was conducted predominantly on men; only recently has this imbalance begun to be redressed.

As scientists continue to probe the interplay between chromosomes, hormones and brain health, it becomes clear that sex matters—not only for understanding disease mechanisms but also for designing effective interventions.

The next decade promises rapid advances as researchers harness new technologies—genomics, advanced neuroimaging and sophisticated biostatistics—to unravel these mysteries at last.

While women’s longer life expectancy contributes somewhat to their increased Alzheimer’s risk, it is biological differences—rooted in chromosomes and hormones—that likely play a larger role. The challenge ahead lies in translating these insights into real-world benefits: earlier detection, better treatments and perhaps even prevention.

This evolving story is one of science at its most dynamic—where each answer opens new questions and where the ultimate aim is nothing less than transforming our approach to a disease that touches millions of lives every year.